Successful Treatment of Severe Subcorneal Pustular Dermatosis with Adalimumab
Jiaoquan Chen,* Yuwu Luo,* Nanji Yu, Yan Yang, Xin Zhou, Shujuan Zhang, Qianru Ye, Huilan Zhu Department of Dermatology, Guangzhou Institute of Dermatology, Guangzhou, Guangdong, 510095, People’s Republic of China*These authors contributed equally to this workCorrespondence:...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2022-11-01
|
| Series: | Clinical, Cosmetic and Investigational Dermatology |
| Subjects: | |
| Online Access: | https://www.dovepress.com/successful-treatment-of-severe-subcorneal-pustular-dermatosis-with-ada-peer-reviewed-fulltext-article-CCID |
| _version_ | 1811320736665567232 |
|---|---|
| author | Chen J Luo Y Yu N Yang Y Zhou X Zhang S Ye Q Zhu H |
| author_facet | Chen J Luo Y Yu N Yang Y Zhou X Zhang S Ye Q Zhu H |
| author_sort | Chen J |
| collection | DOAJ |
| description | Jiaoquan Chen,* Yuwu Luo,* Nanji Yu, Yan Yang, Xin Zhou, Shujuan Zhang, Qianru Ye, Huilan Zhu Department of Dermatology, Guangzhou Institute of Dermatology, Guangzhou, Guangdong, 510095, People’s Republic of China*These authors contributed equally to this workCorrespondence: Huilan Zhu, Department of Dermatology Guangzhou Institute of Dermatology 56 Hengfu Road, Guangzhou, Guangdong, 510095, People’s Republic of China, Email zhlhuilan@126.comAbstract: Subcorneal pustular dermatosis (SPD) is a rare, chronic pustular dermatosis. The pathogenesis of SPD has not been fully elucidated, but some studies have found that tumor necrosis factor (TNF)-α may be associated with its pathogenesis. Some patients with multidrug-resistant SPD have improved significantly after treatment with the anti-TNF-α agent (adalimumab). We present a case of a 28-year-old female with severe SPD who responded rapidly to adalimumab (80mg/week) in combination with acitretin and methylprednisolone within a week. With adalimumab (40 mg next week and followed by 40mg every two weeks) and gradually ceasing other systemic medication, the patient’s condition continued to improve without relapse or side effects. The outcome of this case suggests that adalimumab might be an effective treatment option against multidrug-resistant SPD.Keywords: subcorneal pustular dermatosis, anti-TNF-α agent, adalimumab |
| first_indexed | 2024-04-13T13:04:41Z |
| format | Article |
| id | doaj.art-ed29d0c5c7594a23bfd346299ec74dad |
| institution | Directory Open Access Journal |
| issn | 1178-7015 |
| language | English |
| last_indexed | 2024-04-13T13:04:41Z |
| publishDate | 2022-11-01 |
| publisher | Dove Medical Press |
| record_format | Article |
| series | Clinical, Cosmetic and Investigational Dermatology |
| spelling | doaj.art-ed29d0c5c7594a23bfd346299ec74dad2022-12-22T02:45:50ZengDove Medical PressClinical, Cosmetic and Investigational Dermatology1178-70152022-11-01Volume 152567257079938Successful Treatment of Severe Subcorneal Pustular Dermatosis with AdalimumabChen JLuo YYu NYang YZhou XZhang SYe QZhu HJiaoquan Chen,* Yuwu Luo,* Nanji Yu, Yan Yang, Xin Zhou, Shujuan Zhang, Qianru Ye, Huilan Zhu Department of Dermatology, Guangzhou Institute of Dermatology, Guangzhou, Guangdong, 510095, People’s Republic of China*These authors contributed equally to this workCorrespondence: Huilan Zhu, Department of Dermatology Guangzhou Institute of Dermatology 56 Hengfu Road, Guangzhou, Guangdong, 510095, People’s Republic of China, Email zhlhuilan@126.comAbstract: Subcorneal pustular dermatosis (SPD) is a rare, chronic pustular dermatosis. The pathogenesis of SPD has not been fully elucidated, but some studies have found that tumor necrosis factor (TNF)-α may be associated with its pathogenesis. Some patients with multidrug-resistant SPD have improved significantly after treatment with the anti-TNF-α agent (adalimumab). We present a case of a 28-year-old female with severe SPD who responded rapidly to adalimumab (80mg/week) in combination with acitretin and methylprednisolone within a week. With adalimumab (40 mg next week and followed by 40mg every two weeks) and gradually ceasing other systemic medication, the patient’s condition continued to improve without relapse or side effects. The outcome of this case suggests that adalimumab might be an effective treatment option against multidrug-resistant SPD.Keywords: subcorneal pustular dermatosis, anti-TNF-α agent, adalimumabhttps://www.dovepress.com/successful-treatment-of-severe-subcorneal-pustular-dermatosis-with-ada-peer-reviewed-fulltext-article-CCIDsubcorneal pustular dermatosisanti-tnf-α agentadalimumab |
| spellingShingle | Chen J Luo Y Yu N Yang Y Zhou X Zhang S Ye Q Zhu H Successful Treatment of Severe Subcorneal Pustular Dermatosis with Adalimumab Clinical, Cosmetic and Investigational Dermatology subcorneal pustular dermatosis anti-tnf-α agent adalimumab |
| title | Successful Treatment of Severe Subcorneal Pustular Dermatosis with Adalimumab |
| title_full | Successful Treatment of Severe Subcorneal Pustular Dermatosis with Adalimumab |
| title_fullStr | Successful Treatment of Severe Subcorneal Pustular Dermatosis with Adalimumab |
| title_full_unstemmed | Successful Treatment of Severe Subcorneal Pustular Dermatosis with Adalimumab |
| title_short | Successful Treatment of Severe Subcorneal Pustular Dermatosis with Adalimumab |
| title_sort | successful treatment of severe subcorneal pustular dermatosis with adalimumab |
| topic | subcorneal pustular dermatosis anti-tnf-α agent adalimumab |
| url | https://www.dovepress.com/successful-treatment-of-severe-subcorneal-pustular-dermatosis-with-ada-peer-reviewed-fulltext-article-CCID |
| work_keys_str_mv | AT chenj successfultreatmentofseveresubcornealpustulardermatosiswithadalimumab AT luoy successfultreatmentofseveresubcornealpustulardermatosiswithadalimumab AT yun successfultreatmentofseveresubcornealpustulardermatosiswithadalimumab AT yangy successfultreatmentofseveresubcornealpustulardermatosiswithadalimumab AT zhoux successfultreatmentofseveresubcornealpustulardermatosiswithadalimumab AT zhangs successfultreatmentofseveresubcornealpustulardermatosiswithadalimumab AT yeq successfultreatmentofseveresubcornealpustulardermatosiswithadalimumab AT zhuh successfultreatmentofseveresubcornealpustulardermatosiswithadalimumab |